| UHC Surest Medical and Drug | Hereditary Angioedema (HAE), Treatment and Prophylaxis – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Ilaris® (Canakinumab) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Intracanalicular and Intravitreal Corticosteroid Implants – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Krystexxa® (Pegloticase) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Self-Administered Medications – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Synagis® (Palivizumab) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Collection and Storage of Umbilical Cord Blood Stem Cells | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Electrical Stimulation of the Spine as an Adjunct to Spinal | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Extracorporeal Shock Wave Treatment for Plantar Fasciitis and | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Givosiran for Acute Hepatic Porphyria | 2025-11-01 |